These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37161273)

  • 1. The down-scheduling of MDMA and psilocybin(e): Too fast and too soon.
    Kisely S
    Aust N Z J Psychiatry; 2023 Jul; 57(7):933-934. PubMed ID: 37161273
    [No Abstract]   [Full Text] [Related]  

  • 2. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects.
    Hosanagar A; Cusimano J; Radhakrishnan R
    J Clin Psychiatry; 2021 Feb; 82(2):. PubMed ID: 33988926
    [No Abstract]   [Full Text] [Related]  

  • 6. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. US could soon approve MDMA therapy - opening an era of psychedelic medicine.
    Reardon S
    Nature; 2023 Apr; 616(7957):428-430. PubMed ID: 37076730
    [No Abstract]   [Full Text] [Related]  

  • 8. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2: Review of the Evidence.
    Hosanagar A; Cusimano J; Radhakrishnan R
    J Clin Psychiatry; 2021 Feb; 82(3):. PubMed ID: 33988930
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
    Mithoefer MC; Grob CS; Brewerton TD
    Lancet Psychiatry; 2016 May; 3(5):481-8. PubMed ID: 27067625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
    Jones GM
    J Psychopharmacol; 2023 Jan; 37(1):61-69. PubMed ID: 36314881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.
    Pitts EG; Curry DW; Hampshire KN; Young MB; Howell LL
    Psychopharmacology (Berl); 2018 Feb; 235(2):377-392. PubMed ID: 29248945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.
    Sarparast A; Thomas K; Malcolm B; Stauffer CS
    Psychopharmacology (Berl); 2022 Jun; 239(6):1945-1976. PubMed ID: 35253070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic drugs: the ups and downs of ecstasy.
    Check E
    Nature; 2004 May; 429(6988):126-8. PubMed ID: 15141183
    [No Abstract]   [Full Text] [Related]  

  • 17. Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation.
    Curran HV; Nutt D; de Wit H
    Psychopharmacology (Berl); 2018 Feb; 235(2):373-375. PubMed ID: 29445838
    [No Abstract]   [Full Text] [Related]  

  • 18. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
    Jones GM; Nock MK
    Sci Rep; 2022 Oct; 12(1):16976. PubMed ID: 36216840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nothing Ventured, Nothing Gained: Regulations Cripple Potentially Life-Saving Research of Illicit Substances.
    Abbott KL; Gill KS; Flannery PC; Boothe DM; Dhanasekaran M; Pondugula SR
    ACS Chem Neurosci; 2020 May; 11(10):1382-1384. PubMed ID: 32395981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.